Effects of coexisting upper gastrointestinal symptoms on daily life and quality of life in patients with gastroesophageal reflux disease symptoms

Isshi, Kimio; Furuhashi, Hiroto; Nakada, Koji

doi:10.1007/s10388-020-00801-1

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limitation of this paper is that it only investigated the effects of typical symptoms of GERD and FD on daily life. It has been suggested that atypical symptoms of GERD and FD have a considerable effect on the daily life of patients; 42 thus, prospective clinical studies should investigate the effects of GERD and FD on daily life, including not only typical but also atypical co‐existing symptoms.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and Aim Patients with gastroesophageal reflux disease (GERD) frequently also have functional dyspepsia (FD) symptoms, which impair their quality of life. However, the magnitude and characteristics of the effects of each symptom on daily life have been unclarified. Using multiple regression analysis, we aimed to clarify these questions. Methods We enrolled 290 patients from 29 institutions across Japan, in this prospective, observational study. Patients responded to three questionnaires (Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test [GERD‐TEST], Hospital Anxiety and Depression Scale [HADS], and 8‐item Short‐Form Health Survey [SF‐8]) before and after 4 weeks of proton pump inhibitor treatment. Pearson correlation and multiple regression analyses were conducted between symptoms such as typical GERD, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) of FD, and aspects of daily life, namely, level of satisfaction with the daily life of GERD‐TEST, anxiety and depression score of HADS, and physical and mental component summary of SF‐8. Results Pearson correlation analysis showed a significant correlation in all combinations between GERD/FD‐EPS/FD‐PDS symptoms and the nine aspects of daily life. However, multiple regression analysis results deviated from these results, with the most significant effects seen in the PDS‐symptom subscale (SS) on the five aspects of daily life, that is, dissatisfaction with eating, daily life‐SS, anxiety, depression, and mental component summary (MCS) whereas the significant effects in GERD‐SS on five aspects of daily life, that is, dissatisfaction for eating, anxiety, depression, physical component summary, and MCS, disappeared. Conclusion Dealing with co‐existing FD symptoms without overlooking them may be important in the management of GERD.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gastroesophageal re ux disease and functional dyspepsia (FD) symptoms overlap are very common in gastroenterology outpatient clinics, especially nonerosive re ux disease (NERD) and epigastric pain syndrome (EPS) [1][2] . Studies have shown that this symptomatic overlap not only decreases patients' response to proton pump inhibitors (PPIs) [3] but also increases their psychosocial burden [4] . However, no systematic and effective treatment program has been developed for this disease because its pathogenesis had not been fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome: Study protocol for a multicenter, double-blind, randomized controlled trial

Lv,

Hu,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Practice has shown good efficacy in treating overlapping nonerosive reflux disease (NERD) and epigastric pain syndrome (EPS) symptoms through the use of methods for dispersing the liver and draining heat, harmonizing the stomach and lowering rebelliousness, however, there is a lack of high-level clinical evidence. We intend to evaluate the efficacy and safety of a representative formula of this approach, Tongjiang Granule (TJG), in patients with NERD and EPS symptoms overlapping with liver-stomach disharmony syndrome or liver-stomach depression-heat syndrome (NE-LSDS/LSDHS) in a multicenter clinical randomized controlled trial. Methods/design: This study is designed as a prospective, randomized, double-blind, placebo-controlled clinical trial in which 228 subjects with NE-LSDS/LSDHS will be recruited from 4 research centers. All subjects will be randomized into two groups after signing the informed consent form, the experimental group will be treated with TJG and the control group will be treated with the placebo to mimic TJG (l sachet/dose, 3 times/day, orally, 4 weeks). Visits is scheduled at 6 time points, 2 weeks before dosing and weeks 2, 4, 6, 8, and 10 after dosing. The primary outcome indicator will be the primary symptoms VAS score, the secondary outcome indicators will be the score of atypical and other symptoms, score of traditional Chinese medicine syndrome, visceral sensitivity index scale, patient-reported outcome scale, 36-item short-form scale, and hospital anxiety and depression scale. The safety indicators will include pre- and postdose blood, urine routine, stool routine with occult blood, liver and renal function, electrocardiogram, 24-hour esophageal pH impedance (1/3 of subjects), predose urine pregnancy test, and gastroscopy. Adverse events will also be promptly recorded. Discussion This study will evaluate the efficacy and safety of TJG for the treatment of patients with NE-LSDS/LSDHS, and the results will provide high-level clinical research-based evidence for the application of TJG NE-LSDS/LSDHS. Trial registration: ClinicalTrial.gov NCT05312463. Registered on 3 March 2022. All items from the World Health Organization Trial Registration Data Set can be found at https://classic.clinicaltrials.gov/ct2/show/NCT05312463.

show abstract

“…One of the main GERD complaints about heartburn that adversely affect a patient's life quality. Therefore, the aim of treatment to improve the quality of life by quickly alleviating their symptoms [2] .…”

Section: Introductionmentioning

confidence: 99%

“…It consists of 7 acidreflux related and 5 symptoms of dysmotility [No. 2,3,5,8,11] of GERD the higher scores the more directive to GERD [Table 3] [11] . Patients were examined clinically and the basic laboratory investigations were done [CBC, ESR, S. creatinine, S. Urea, ALT, AST, S. Albumin, S. Bilirubin, PT, PTT, INR] and Upper endoscopy with biopsy to exclude Barrett's esophagus before the start of treatment.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study Between the Efficacies of Vonoprazan Versus Omeprazole in Patients with Gastroesophageal Reflux Disease

Mahdi

Al-Zhaby²,

Abdelhalim³

et al. 2023

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: The most commonly known abnormality of gastric acidity is gastroesophageal reflux disease [GERD] which is treated by proton pump inhibitors [PPIs]. One of the new family of gastric acid-suppressing medications is vonoprazan that works as a potassium-competitive acid blocker [P-CABs]. Aim of the Work:To compare the effectiveness of 20 mg vonoprazan versus omeprazole 40 mg once daily half an hour before breakfast as a treatment of symptoms and mucosal healing in GERD patients.Patients and Methods: Sixty cases, proven to have GERD, were enrolled in a comparative clinical trial after having upper endoscopes. Cases were classified into two groups, 30 patients each; group [A] received omeprazole 40 mg once daily, whereas group [B] received vonoprazan 20 mg once daily for 8 weeks, then reevaluation of both groups by symptoms relief using GERD Q score, frequency scale of the symptoms of gastroesophageal reflux disease questionnaire [FSSG] and upper endoscopy was done for all patients after 8 weeks. For each patient, medical history taking, clinical examination, routine laboratory investigations, and upper endoscopy with GERD classification according to LA classification were done.Results: No detected differences between the included groups regarding GERD Q Score and FSSG score. Our data showed that complete symptoms resolution was somewhat higher among the omeprazole group compared to the vonoprazan group without a statistically significant difference. There is a significant decrease in reflux score, and total score in both groups however, the drop in FSSG scores was more significant in group A in comparison to group B. Conclusion:Vonoprazan showed no superiority over omeprazole in relief of typical symptoms and mucosal healing in patients with GERD; the drop in FSSG scores was more significant in omeprazole group compared to vonoprazan group.

show abstract

Effects of coexisting upper gastrointestinal symptoms on daily life and quality of life in patients with gastroesophageal reflux disease symptoms

Cited by 5 publications

References 30 publications

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

Assessment of the Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome: Study protocol for a multicenter, double-blind, randomized controlled trial

Comparative Study Between the Efficacies of Vonoprazan Versus Omeprazole in Patients with Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About